STOCK TITAN
  1. Home
  2. Sec-filings
  3. KRYS
  4. [Form 4] Krystal Biotech, Inc. Insider Trading Activity

Krystal Biotech (KRYS) CEO trades 25,000 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Krystal Biotech, Inc.’s President and CEO Krish S. Krishnan reported open-market sales of 25,000 shares of common stock on June 4, 2026. The shares were sold in multiple trades with reported weighted average prices such as $312.23 and $300.75 per share.

The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to terminate on December 4, 2026 or earlier under its terms. After these transactions, Krishnan directly holds 1,474,933 shares and indirectly holds 90,000 shares through the SMK Trust FBO KSK and 50,000 shares through the Krishnan Family Trust, where he shares voting and investment power. Shares directly owned by his spouse are reported separately and are disclaimed except for any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Krishnan Krish S
Role President and CEO
Sold 25,000 shs ($7.70M)
Type Security Shares Price Value
Sale Common Stock 320 $300.75 $96K
Sale Common Stock 640 $302.2367 $193K
Sale Common Stock 176 $303.1689 $53K
Sale Common Stock 544 $304.8102 $166K
Sale Common Stock 589 $306.3318 $180K
Sale Common Stock 11,461 $307.6776 $3.53M
Sale Common Stock 4,830 $308.4677 $1.49M
Sale Common Stock 2,784 $309.4901 $862K
Sale Common Stock 2,652 $310.429 $823K
Sale Common Stock 964 $311.358 $300K
Sale Common Stock 40 $312.23 $12K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,474,933 shares (Direct, null); Common Stock — 90,000 shares (Indirect, By SMK Trust FBO KSK)
Footnotes (1)
  1. The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025, and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. The transaction was executed in multiple trades ranging from $302.05 to $303.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $303.05 to $303.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $304.07 to $304.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $306.00 to $306.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $307.03 to $308.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $308.03 to $309.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $309.04 to $310.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $310.06 to $311.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $311.07 to $311.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Held by SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. Held by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
Shares sold 25,000 shares Total common shares sold on June 4, 2026
Sale price example $312.23/share Weighted average price for one reported sale tranche
Sale price example $300.75/share Weighted average price for another sale tranche
Direct holdings after sale 1,474,933 shares Common shares directly owned following transactions
Indirect SMK Trust holdings 90,000 shares Held by SMK Trust FBO KSK with shared voting and investment power
Indirect Family Trust holdings 50,000 shares Held by Krishnan Family Trust with joint voting and investment control
10b5-1 plan adoption date September 4, 2025 Date CEO adopted Rule 10b5-1 trading plan
10b5-1 plan term Dec 4, 2025–Dec 4, 2026 Plan start and scheduled termination dates
Rule 10b5-1 trading plan regulatory
"The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
irrevocable trust financial
"Held by SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krishnan Krish S
(Last)(First)(Middle)
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
(Street)
PITTSBURGH PENNSYLVANIA 15203
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026S(1)320(2)D$300.751,474,933D
Common Stock06/04/2026S640D$302.2367(3)1,474,293D
Common Stock06/04/2026S176D$303.1689(4)1,474,117D
Common Stock06/04/2026S544D$304.8102(5)1,473,573D
Common Stock06/04/2026S589D$306.3318(6)1,472,984D
Common Stock06/04/2026S11,461D$307.6776(7)1,461,523D
Common Stock06/04/2026S4,830D$308.4677(8)1,456,693D
Common Stock06/04/2026S2,784D$309.4901(9)1,453,909D
Common Stock06/04/2026S2,652D$310.429(10)1,451,257D
Common Stock06/04/2026S964D$311.358(11)1,450,293D
Common Stock06/04/2026S40D$312.231,450,253D
Common Stock90,000IBy SMK Trust FBO KSK(12)
Common Stock50,000IBy Krishnan Family Trust(13)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
2. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025, and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
3. The transaction was executed in multiple trades ranging from $302.05 to $303.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
4. The transaction was executed in multiple trades ranging from $303.05 to $303.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
5. The transaction was executed in multiple trades ranging from $304.07 to $304.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
6. The transaction was executed in multiple trades ranging from $306.00 to $306.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
7. The transaction was executed in multiple trades ranging from $307.03 to $308.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
8. The transaction was executed in multiple trades ranging from $308.03 to $309.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
9. The transaction was executed in multiple trades ranging from $309.04 to $310.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
10. The transaction was executed in multiple trades ranging from $310.06 to $311.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
11. The transaction was executed in multiple trades ranging from $311.07 to $311.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
12. Held by SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
13. Held by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
Remarks:
/s/ Krish S. Krishnan06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Krystal Biotech (KRYS) CEO Krish Krishnan report in this Form 4?

He reported open-market sales of 25,000 shares of Krystal Biotech common stock. The trades occurred on June 4, 2026 and were executed in multiple transactions at different prices, all disclosed as sales of non-derivative common stock.

How many Krystal Biotech (KRYS) shares did the CEO sell and at what prices?

He sold a total of 25,000 common shares in several open-market trades. Reported weighted average sale prices include $312.23 per share in one trade and $300.75 per share in another, with additional transactions at intermediate price levels.

Was the Krystal Biotech (KRYS) CEO’s stock sale part of a Rule 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5-1 trading plan. The plan was adopted on September 4, 2025, commenced on December 4, 2025, and is scheduled to terminate on December 4, 2026 or earlier under its terms.

How many Krystal Biotech (KRYS) shares does the CEO hold after these transactions?

Following the reported sales, he directly owns 1,474,933 common shares. He also has indirect holdings of 90,000 shares through the SMK Trust FBO KSK and 50,000 shares through the Krishnan Family Trust, where he shares voting and investment power.

Are the Krystal Biotech (KRYS) shares owned by the CEO’s spouse included in this Form 4?

No. The footnotes state that shares directly owned by his spouse, Suma M. Krishnan, and her transactions are reported separately. He disclaims beneficial ownership of those shares except to the extent of his pecuniary interest in them.

What is the role of the trusts mentioned in the Krystal Biotech (KRYS) Form 4?

The SMK Trust FBO KSK is an irrevocable trust where he serves as co-trustee and shares voting and investment power. The Krishnan Family Trust is jointly beneficially owned by him and his spouse, with joint voting and investment control over its 50,000 shares.